[
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics",
    "summary": "T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=22180e22df7c14ec33162ab891f96bea3a0e7a178cd9767eb9209acc9bd93aa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735224180,
      "headline": "The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics",
      "id": 132164919,
      "image": "https://media.zenfs.com/en/zacks.com/03f63cde809dc0b9100c223e177450af",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=22180e22df7c14ec33162ab891f96bea3a0e7a178cd9767eb9209acc9bd93aa5"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip",
    "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial.  Vertex is best known for its therapies for the rare lung disease cystic fibrosis (CF).  Its steady work over the year delivered a large market share in CF therapies.",
    "url": "https://finnhub.io/api/news?id=bc6828dbe71cce234e47eb4bf8fac802a80553fafb8874593f0a6bc4360b1ff0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735219800,
      "headline": "Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip",
      "id": 132165191,
      "image": "https://g.foolcdn.com/editorial/images/801997/two-investors-consider-a-stock-with-laptop.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial.  Vertex is best known for its therapies for the rare lung disease cystic fibrosis (CF).  Its steady work over the year delivered a large market share in CF therapies.",
      "url": "https://finnhub.io/api/news?id=bc6828dbe71cce234e47eb4bf8fac802a80553fafb8874593f0a6bc4360b1ff0"
    }
  }
]